Retrospective analysis compares ASCT and anti-CD38 regimens in elderly multiple myeloma patients, highlighting impacts of frailty.status.
Key Points
Elderly multiple myeloma patients receiving autologous stem cell transplantation had a similar progression-free survival as those on anti-CD38 therapies.
The response rate was 94% in the ASCT cohort compared to 91% in the no-ASCT cohort, indicating overall high efficacy in both treatment groups.
Analysis evaluated outcomes of patients aged 65-75 receiving ASCT versus non-transplant eligible anti-CD38 therapies, incorporating frailty assessments.
Toxicity appeared higher in the ASCT group, with severe hematologic events more common than in the no-ASCT cohort, indicating distinct safety profiles.